Key Drivers
- Positive gross margin
- Negative free cash
- High leverage
AIAI Summary
Maravai is shifting from a pandemic-volume growth bet to a turnaround focused on cash generation—anchored by high-margin BST and >$50M annualized cost cuts that could drive adjusted-EBITDA positivity, but near-term solvency hinges on converting BST cross-sell into repeatable GMP revenue and executing restructuring without cash shortfalls or debt stress.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive gross margin
- •Negative free cash
- •High leverage
MRVI has healthy gross margins and sizable tangible/investment assets but is weighed down by persistent operating losses, deeply negative free cash flow, no reported cash balance, and a highly leveraged balance sheet. #cash-strained
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Former support flipped
- •Lower highs forming
MRVI is in a short-term downtrend: last month's SMA ≈ $3.35 vs last trade $2.98 (≈11% below), price has moved from a ~$3.82 peak into lower highs and sits below prior support, so bearish bias until it reclaims the $3.35 SMA or the $3.50–$3.82 resistance band.
Last month high-to-low range ~$3.82 to $2.98 (~22%) signaling elevated volatility
Sentiment & News
Key News Insights:
- •Modest revenue beat
- •Improved EPS loss
- •Still net-loss
Maravai posted a modest Q4 revenue beat ($49.9M vs ~$49.1M) and improved EPS loss but remains net‑loss making for FY25 with $185.7M in revenue.
The results may modestly support the stock on execution progress but limited upside given continued unprofitability and uncertain path to sustained profitability
Similar Companies in Healthcare
Other companies in the same sector with AI ratings